{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:04:29Z","timestamp":1792598669735,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13256-019-2002-2","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T01:02:32Z","timestamp":1553562152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the\u00a0literature"],"prefix":"10.1186","volume":"13","author":[{"given":"Nobumasa","family":"Ohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Yoneoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"2002_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","volume":"20","author":"GK Pennock","year":"2015","unstructured":"Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20:812\u201322.","journal-title":"Oncologist"},{"key":"2002_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"2002_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173\u201382.","journal-title":"JAMA Oncol"},{"key":"2002_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","volume":"38","author":"PB Araujo","year":"2015","unstructured":"Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV. Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Investig. 2015;38:1159\u201366.","journal-title":"J Endocrinol Investig"},{"key":"2002_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19:82\u201392.","journal-title":"Pituitary"},{"key":"2002_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/imt-2016-0147","volume":"9","author":"YH Shang","year":"2017","unstructured":"Shang YH, Zhang Y, Li JH, Li P, Zhang X. Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. Immunotherapy. 2017;9:261\u201372.","journal-title":"Immunotherapy."},{"key":"2002_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","volume":"63","author":"Y Okano","year":"2016","unstructured":"Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, Tomaru T, Nakajima Y, Ishii S, Ozawa A, Shibusawa N, Shimada T, Higuchi T, Chikamatsu K, Yamada M. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63:905\u201312.","journal-title":"Endocr J"},{"key":"2002_CR8","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/1346-8138.13532","volume":"44","author":"T Fujimura","year":"2017","unstructured":"Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R, Aiba S. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient. J Dermatol. 2017;44:e13\u20134.","journal-title":"J Dermatol"},{"key":"2002_CR9","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1111\/1346-8138.13571","volume":"44","author":"A Narahira","year":"2017","unstructured":"Narahira A, Yanagi T, Cho KY, Nakamura A, Miyoshi H, Hata H, Imafuku K, Kitamura S, Shimizu H. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy. J Dermatol. 2017;44:e70.","journal-title":"J Dermatol"},{"key":"2002_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/1346-8138.13437","volume":"44","author":"M Ishikawa","year":"2017","unstructured":"Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol. 2017;44:109\u201310.","journal-title":"J Dermatol"},{"key":"2002_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jjco\/hyx018","volume":"47","author":"K Kitajima","year":"2017","unstructured":"Kitajima K, Ashida K, Wada N, Suetsugu R, Takeichi Y, Sakamoto S, Uchi H, Matsushima T, Shiratsuchi M, Ohnaka K, Furue M, Nomura M. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Jpn J Clin Oncol. 2017;47:463\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"2002_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1507\/endocrj.EJ16-0596","volume":"64","author":"KY Cho","year":"2017","unstructured":"Cho KY, Miyoshi H, Nakamura A, Kurita T, Atsumi T. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [letter]. Endocr J. 2017;64:235\u20136.","journal-title":"Endocr J"},{"key":"2002_CR13","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2169\/internalmedicine.8548-16","volume":"56","author":"K Takaya","year":"2017","unstructured":"Takaya K, Sonoda M, Fuchigami A, Hiyoshi T. Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer. Intern Med. 2017;56:2463\u20139.","journal-title":"Intern Med"},{"key":"2002_CR14","first-page":"115","volume":"42","author":"T Seki","year":"2017","unstructured":"Seki T, Yasuda A, Oki M, Kitajima N, Takagi A, Nakajima N, Miyajima A, Fukagawa M. Secondary adrenal insufficiency following nivolumab therapy in a patient with metastatic renal cell carcinoma. Tokai J Exp Clin Med. 2017;42:115\u201320.","journal-title":"Tokai J Exp Clin Med"},{"key":"2002_CR15","doi-asserted-by":"publisher","first-page":"e000217","DOI":"10.1136\/esmoopen-2017-000217","volume":"2","author":"M Kastrisiou","year":"2017","unstructured":"Kastrisiou M, Kostadima FL, Kefas A, Zarkavelis G, Kapodistrias N, Ntouvelis E, Petrakis D, Papadaki A, Vassou A, Pentheroudakis G. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. ESMO Open. 2017;2:e000217.","journal-title":"ESMO Open"},{"key":"2002_CR16","doi-asserted-by":"publisher","first-page":"e8426","DOI":"10.1097\/MD.0000000000008426","volume":"96","author":"MF Zeng","year":"2017","unstructured":"Zeng MF, Chen L, Ye HY, Gong W, Zhou LN, Li YM, Zhao XL. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review. Medicine (Baltimore). 2017;96:e8426.","journal-title":"Medicine (Baltimore)"},{"key":"2002_CR17","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1016\/j.jtho.2017.07.021","volume":"12","author":"L Marchand","year":"2017","unstructured":"Marchand L, Paulus V, Fabien N, P\u00e9rol M, Thivolet C, Vouillarmet J, Saintigny P. Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol. 2017;12:e182\u20134.","journal-title":"J Thorac Oncol"},{"key":"2002_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","volume":"57","author":"N Ohara","year":"2018","unstructured":"Ohara N, Ohashi K, Fujisaki T, Oda C, Ikeda Y, Yoneoka Y, Hashimoto T, Hasegawa G, Suzuki K, Takada T. Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review. Intern Med. 2018;57:527\u201335.","journal-title":"Intern Med"},{"key":"2002_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.14740\/jocmr3257w","volume":"10","author":"K Takebayashi","year":"2018","unstructured":"Takebayashi K, Ujiie A, Kubo M, Furukawa S, Yamauchi M, Shinozaki H, Suzuki T, Naruse R, Hara K, Tsuchiya T, Inukai T. Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma. J Clin Med Res. 2018;10:358\u201362.","journal-title":"J Clin Med Res"},{"key":"2002_CR20","first-page":"345","volume":"32","author":"H Ariyasu","year":"2018","unstructured":"Ariyasu H, Inaba H, Ota T, Yamaoka H, Furukawa Y, Iwakura H, Doi N, Yamamoto Y, Akamizu T. Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma. In Vivo. 2018;32:345\u201351.","journal-title":"In Vivo."},{"key":"2002_CR21","first-page":"4229","volume":"37","author":"R Ariyasu","year":"2017","unstructured":"Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M. Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res. 2017;37:4229\u201332.","journal-title":"Anticancer Res"},{"key":"2002_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/js.2017-00414","volume":"2","author":"K Kanie","year":"2017","unstructured":"Kanie K, Iguchi G, Bando H, Fujita Y, Odake Y, Yoshida K, Matsumoto R, Fukuoka H, Ogawa W, Takahashi Y. Two cases of atezolizumab-induced hypophysitis. J Endocr Soc. 2017;2:91\u20135.","journal-title":"J Endocr Soc"},{"key":"2002_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11102-006-0408-5","volume":"9","author":"M Andrioli","year":"2006","unstructured":"Andrioli M, Pecori Giraldi F, Cavagnini F. Isolated corticotrophin deficiency. Pituitary. 2006;9:289\u201395.","journal-title":"Pituitary"},{"key":"2002_CR24","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","volume":"378","author":"P Goldstraw","year":"2011","unstructured":"Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727\u201340.","journal-title":"Lancet"},{"key":"2002_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u20134.","journal-title":"Eur J Cancer"},{"key":"2002_CR26","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(17)30703-1","volume":"390","author":"L Chaker","year":"2017","unstructured":"Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390:1550\u201362.","journal-title":"Lancet"},{"key":"2002_CR27","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/S0140-6736(16)30053-8","volume":"388","author":"CE Higham","year":"2016","unstructured":"Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet. 2016;388:2403\u201315.","journal-title":"Lancet"},{"key":"2002_CR28","first-page":"1537","volume":"34","author":"S Lauro","year":"2014","unstructured":"Lauro S, Onesti CE, Righini R, Marchetti P. The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res. 2014;34:1537\u201345.","journal-title":"Anticancer Res"},{"key":"2002_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/14740338.2017.1313226","volume":"16","author":"O Arrieta","year":"2017","unstructured":"Arrieta O, Zatarain-Barr\u00f3n ZL, Cardona AF, Carmona A, Lopez-Mejia M. Ramucirumab in the treatment of non-small cell lung cancer. Expert Opin Drug Saf. 2017;16:637\u201344.","journal-title":"Expert Opin Drug Saf"},{"key":"2002_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/cen.12969","volume":"84","author":"N Kyriakakis","year":"2016","unstructured":"Kyriakakis N, Lynch J, Orme SM, Gerrard G, Hatfield P, Loughrey C, Short SC, Murray RD. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. Clin Endocrinol. 2016;84:372\u20139.","journal-title":"Clin Endocrinol"},{"key":"2002_CR31","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4158\/EP171832.OR","volume":"23","author":"G O\u2019Malley","year":"2017","unstructured":"O\u2019Malley G, Lee HJ, Parekh S, Galsky MD, Smith CB, Friedlander P, Yanagisawa RT, Gallagher EJ. Rapid evolution of thyroid dysfunction in patients treated with nivolumab. Endocr Pract. 2017;23:1223\u201331.","journal-title":"Endocr Pract"},{"key":"2002_CR32","first-page":"1035","volume":"31","author":"T Maekura","year":"2017","unstructured":"Maekura T, Naito M, Tahara M, Ikegami N, Kimura Y, Sonobe S, Kobayashi T, Tsuji T, Minomo S, Tamiya A, Atagi S. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer. In Vivo. 2017;31:1035\u20139.","journal-title":"In Vivo"},{"key":"2002_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.autrev.2014.01.021","volume":"13","author":"A Falorni","year":"2014","unstructured":"Falorni A, Minarelli V, Bartoloni E, Alunno A, Gerli R. Diagnosis and classification of autoimmune hypophysitis. Autoimmun Rev. 2014;13:412\u20136.","journal-title":"Autoimmun Rev"},{"key":"2002_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.autrev.2013.07.006","volume":"13","author":"M Cutolo","year":"2014","unstructured":"Cutolo M. Autoimmune polyendocrine syndromes. Autoimmun Rev. 2014;13:85\u20139.","journal-title":"Autoimmun Rev"},{"key":"2002_CR35","first-page":"253","volume":"64","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Maruyama H, Nishiyama M, Asaba K, Ikeda Y, Takao T, Iwasaki Y, Kumon Y, Suehiro T, Tanimoto N, Mizobuchi M, Nakamura T. Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. Horm Res. 2005;64:253\u201360.","journal-title":"Horm Res"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2002-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-019-2002-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2002-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:09:14Z","timestamp":1585094954000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-019-2002-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2002"],"URL":"https:\/\/doi.org\/10.1186\/s13256-019-2002-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"6 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"88"}}